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Objective: The purpose of this study was to examine the acute effectiveness of manualized exposure-
based CBT with a family-based treatment, as an initial treatment for pediatric OCD delivered in regu-
lar community child and adolescents outpatient clinics. The report summarizes outcome of the ﬁrst
treatment step in the NordLOTS, which was conducted in Denmark, Sweden and Norway.
Method: 269 participants, age 7e17, with OCD, received treatment for 14 weekly sessions. Treatment
response was deﬁned as CY-BOCS score of 15 at post treatment.
Results: 241 participants (89.6%) completed all 14 weeks of treatment. Treatment response among the
completers was 72.6% (95% CI 66.7%e77.9%). Mixed effects model revealed a statistically signiﬁcant effect
of time F(1,479) ¼ 130.434. Mean symptom reduction on the CY-BOCS was 52.9% (SD ¼ 30.9). The
estimated within-group effect size between baseline and post treatment was 1.58 (95% CI: 1.37e1.80).
Conclusion: This study found that manualized CBT can be applied effectively in community mental health
clinics. These ﬁndings underscore the feasibility of implementing exposure-based CBT for pediatric OCD
in a regular child and adolescent mental health setting.
Clinical trials registration information: This study was registered in Current Controlled Trials; Nordic
Long-term Obsessive-compulsive disorder (OCD) Treatment Study (www.controlled-trials.com
ISRCTN66385119).
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Is it possible to conduct effective treatment for pediatric
obsessive-compulsive disorder (OCD) in regular community child
and adolescents outpatient clinics? As demonstrated in many open
and randomized controlled trials (RCTs), exposure-based cognitive
behavioral therapy (CBT) is an efﬁcacious treatment for children
and adolescents with OCD. These trials were conducted primarily inscent Mental Health, Eastern
orp).
Ltd. This is an open access article uuniversity-based clinics, and thus the generalizability of their
ﬁndings needs to be established in regular community settings.
OCD is characterized by recurrent obsessions and compulsions.
Symptoms of OCD in youth are diverse and largely convergent with
symptom proﬁles seen in adults (Bloch, Landeros-Weisenberger,
Rosario, Pittenger, & Leckman, 2008). Prevalence studies estimate
that between 0.5% and 3% of children and adolescents suffer from
OCD (Heyman et al., 2003; Leonard et al., 1993), childhood or
adolescent onset is seen in up to 50% of adult cases (Geller et al.,
1998; Nelson & Rice, 1997; Riddle, 1998; Taylor, Asmundson, &
Jang, 2011).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
The Mean, SD and effect size of pediatric OCD studies.
Studies CY-BOCS
pre
CY-BOCS
post
SD
pre
SD
post
Sample
size
ES
Barrett (2004) 21.4 8.4 5.6 6.9 22 1.66
Freeman (2014) 26.0 12.3 4.0 5.4 63 2.32
Piacentini (2011) 24.7 13.3 4.7 8.2 49 1.41
POTS (2004) 26.0 14.0 4.6 9.5 28 1.35
Reynolds (2013) 24.3 14.3 4.6 8.6 25 1.21
Storch (2013) 25.1 16.4 4.0 8.6 31 1.10
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tioning, with a ﬂuctuating course and high risk of chronic outcomes
(Piacentini, Bergman, Keller, & McCracken, 2003; Thomsen, 2000).
OCD related impairment interferes with the child's daily func-
tioning (family, social and academic performance), and may have
an adverse impact on the child's psychosocial development (Peris
et al., 2008; Piacentini et al., 2003; Storch et al., 2007;
Valderhaug & Ivarsson, 2005).
Controlled clinical trials with young people diagnosed with
OCD support the efﬁcacy of CBT as well as medication with sero-
tonin reuptake inhibitors (SRI) (Abramowitz, Whiteside, & Deacon,
2005; Geller, Biederman, Stewart, Mullin, Martin, et al., 2003;
Watson & Rees, 2008). International expert guidelines recom-
mend the use of exposure-based CBT as a ﬁrst-line of treatment
for children and adolescents with OCD (NICE, 2005) and SRI or
combined treatment (CBT plus SRI) for moderate to severe OCD
(Geller et al., 2012). These recommendations are supported by
meta-analyses of randomized controlled trials for pediatric OCD,
with between group effect size (ES) estimates of 1.45 (95%
CI ¼ 0.68e2.22) for CBT and 0.48 (95% CI ¼ 0.36e0.61) for phar-
macotherapy (Abramowitz et al., 2005; Geller, Biederman, Stewart,
Mullin, Farrell, et al., 2003; Watson & Rees, 2008). Even though
the data are clear and several international guidelines recommend
exposure-based CBT as the ﬁrst line of treatment for pediatric
OCD, few patients actually receive this treatment in child and
adolescent mental health clinics (AACAP, 2012; Abramowitz et al.,
2005; NICE, 2005; Watson & Rees, 2008). Evaluating the effec-
tiveness of exposure-based CBT outside the context of carefully
controlled clinical trials represents an important next step in
promoting the use of this efﬁcacious treatment in a wider variety
of clinical settings.
The Nordic Long-term OCD Treatment Study (NordLOTS) is a
clinical trial based on a stepped-care treatment model, conducted
in three Scandinavian countries (Denmark, Norway and Sweden).
The treatment components evaluated in NordLOTS (CBT and SRI)
were those with the strongest evidence base (Geller et al., 2012;
NICE, 2005). The purpose of The NordLOTS study was: (1) to
examine treatment outcome of exposure-based CBT in community
mental health clinics (ﬁrst step), (2) to identify CBT non-
responders; (3) to investigate whether an increased number of
CBT sessions or medication offered non-responders would yield the
best outcome (second step), and (4) to study the long-term dura-
bility of treatment by following patients over three years post
treatment.
The current paper addresses the ﬁrst aim (point number one)
examining outcome of exposure-based CBT in community settings.
Second step treatment outcome will be discussed elsewhere, and
data collection for follow-up is ongoing. Overall rationale and de-
tails of the entire NordLOTS design have been described elsewhere
(Ivarsson et al., 2010; Thomsen et al., 2013).
Effectiveness trials aim to determine whether treatments are
efﬁcacious in natural settings and intend to measure beneﬁcial
effects across a more heterogenous population (i.e., more comor-
bidities and more diverse treatment history), thus being closer to
“real word settings” (Godwin et al., 2003). One of the main issues in
evidence based practice (EBP) is the extent to which results from
RCTs can be generalized to community mental health clinics, and to
patients being treated in such clinics.
The efﬁcacy of exposure-based (CBT) has been clearly estab-
lished, and the groundwork which has been laid with respect to
examining exposure-based CBT effectiveness, is summarized in
Table 1. This study sets the stage for a broader examination of
exposure-based CBT, the transportability to the very setting in
which most OCD patients receive clinical services. We argue that
the transportability of efﬁcacy-validated treatments to communitymental health clinics is an important empirical question that war-
rants answers driven by data.
The aim of the present paperwas to examine the effectiveness of
exposure-based CBT for pediatric OCD patients in community
mental health setting. We hypothesized that exposure-based CBT
delivered in community mental health clinics would be effectively
and feasibly delivered, resulting in a signiﬁcant change in CY-BOCS
total score from pre to post-treatment, with an effect size
approaching those reported in efﬁcacy studies.
Methods
Study design
NordLOTS is based on a stepped-care treatment model. The ﬁrst
step was an open uncontrolled clinical trial, with fourteen sessions
of exposure-based CBT to all participants. Assessment points were
at baseline, weeks 7 and 14 (post treatment), assessed by inde-
pendent evaluators (IEs) using the Children Yale-Brown Obsessive
Compulsive Scale (CY-BOCS). The CY-BOCS is a clinician-rated in-
strument that combines data from clinical observations, and child
and parent reports, CY-BOCS assess obsessions and compulsions
separately. As the primary scalar outcome variable, the CY-BOCS
total score provides an indication of the degree of change (see
Measures).
Clinics
Clinics participating in NordLOTS were public community
mental health clinics, with general referrals, that serve children and
adolescents 18 years or younger with a range of emotional and
behavioral problems. The community mental health services are a
part of the general national health services, provided free of charge.
All the NordLOTS clinics were similar in terms of their organization,
referral procedures and service provided, with the exception that
the therapists at the OCD clinics (Aarhus and Gothenburg) mostly
treated patients with OCD.
Five main study sites participated: (1) The OCD-clinic, Regional
Center for Child and Adolescent Psychiatry, Risskov, Aarhus Uni-
versity Hospital, Denmark, (2) The Centre for Child and Adolescent
Mental Health Eastern and Southern, Oslo, Norway, (3) The
Regional Centre for Child and Adolescent Mental Health, Mid-
Norway, Trondheim, Norway, (4) BUP Signal in Stockholm, Swe-
den, with an additional 8 other community mental health clinics,
and (5) The OCD-clinic, Queen Silvia Children's Hospital, Gothen-
burg, Sweden (Table 2.).
Therapists
The study-therapists were either psychiatrists, clinical psy-
chologists or certiﬁed psychotherapists. Half of the therapists had
ﬁve to ten years of clinical experience, while the other half had ten
years or more. Therapist's prior experience with exposure-based
Table 2
Number of therapist and patients for each site.
Site Aarhus
Denmark
Gothenburg
Sweden
Stockholm
Sweden
Southern-
eastern
Norway
Central
Norway
Total
Number of
patients
80 48 30 41 70 269
Number of
clinics at
each site
1 1 9 5 4 20
Number of
therapist
6 3 12 9 14 44
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therapists at the two OCD clinics had more experience with
exposure-based CBT for OCD. At the remaining three sites, which
included 18 smaller community mental health clinics, few of the
therapists had prior training in exposure-based CBT for OCD. Forty-
four therapists provided the exposure-based CBT (Table 2). The
number of patients per therapist varied to a large degree both be-
tween and within sites. Nine of the forty-four therapists treated
more than ten patients, ﬁve treated only one patient. One hundred
and ﬁfty-one of the patients (56.1%) came from an OCD clinic
(Table 3).
Training in exposure-based CBT varied according to the thera-
pist's prior experience treating pediatric OCD. The pre-experience
level of CBT treatment at each site was a deciding factor when
determining the degree of pre-study therapist training at each site.
Leadership at each site decided the necessity and intensity of CBT
training prior to the study in an agreement with the PI of the
NordLOTS trial. Therapists at sites with little or no prior CBT
experience received ten days of training with the NordLOTS treat-
ment manual. They also received monthly group supervision, for
three consecutive hours, at their respective sites throughout the
study. Experienced doctor-level clinical psychologists and psychi-
atrists, were responsible for the CBT training and supervision. The
therapists at the two OCD clinics studied the NordLOTS manual
prior to study start without additional training or supervision.
Participants
Patients were referred from community health centers, general
practitioners or parents who contacted the clinics directly. To
ensure a representative sample of pediatric patients seeking
treatment for OCD, exclusion criteria were kept to a minimum. A
total of 767 children and adolescents were screened for participa-
tion, 491 met inclusion criteria for assessment, and 269 wereTable 3
Number of patient for each therapists.
Number of patients Number of therapists
1 5
2 10
3 6
4 6
5 5
6 1
7 2
11 3
12 1
14 1
19 1
20 1
23 1
37 1included in step 1 (Fig. 1). The mean baseline CY-BOCS total score
was 24.6 (SD 5.1), subscale scores for obsession 12.3 (SD 2.8) and
compulsion 12.3 (SD 2.7). Child age ranged from 7 to 17 years, mean
12.8 (SD 2.7) years. Genders were equally represented, females
51.3% (n¼ 138). The samplewas primarily of Scandinavian ethnicity
as 97% (n ¼ 261) had either mother, father or both of Scandinavian
origin. Almost half (40.5%, n ¼ 109) of the patients had one or more
comorbid psychiatric disorder (Table 4).
Patients were included into the study if they fulﬁlled the
following criteria: (1) primary diagnosis of OCD in accordance with
the criteria in the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (American
Psychiatric Association, 2000), (2) CY-BOCS entry score 16, (3)
7e17 years of age, and (4) patients with attention-deﬁcit-
hyperactivity disorder (ADHD) were eligible, after having been
stabilized on medication for at least 3 months prior to entry.
Exclusion criteria included: (1) the presence of other psychiatric
disorders (according to the DSM-IV) having a higher treatment
priority (i.e., psychosis and severe depression), (2) any speciﬁc
developmental disorder (i.e., pervasive developmental disorder
[PDD] or Asperger's disorder). However, a diagnosis of PDD NOSFig. 1. Flow diagram of the NordLOTS treatment study.
Table 4
Baseline demographic and clinical characteristics and observed cases by time point.
Variable Total Aarhus OCD clinic Gothen. OCD clinic Stockh. East/South Norway Central Norway p-value
Age, mean (SD) 12.8 (2.7) 12.5 (2.7) 13.0 (2.4) 12.9 (2.8) 14 (2.5) 12.3 (12.3) .024
Sex N (%)
Male 131 (48.7) 32 (40) 21 (43.8) 9 (30.0) 30 (73.2) 39 (55.7) .001
Female 138 (51.3) 48 (60) 27 (56.3) 21 (70.0) 11 (26.8) 31 (44.3)
Family status
Parents living together 174 (64.7) 51 (63.7) 30 (62.5) 24 (80.0) 26 (63.4) 43 (61.4) .102
Divorced 91 (33.8) 25 (31.3) 18 (37.5) 6 (20.0) 15 (36.6) 27 (38.6)
Other 4 (1.5) 4 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
SES
Major/medium business and
major/minor professional
140 (53.4) 34 (43.0) 26 (54.2) 19 (63.3) 32 (78.0) 29 (45.3) .003
Skilled craftsmen to unskilled laborers 122 (46.6) 45 (57.0) 22 (45.8) 11 (36.7) 9 (22.0) 35 (54.7)
Ethnicity
Scandinavian children (Mother or
father Scandinavian)
261 (97) 80 (100) 44 (91.7) 27 (90.0) 40 (97.6) 70 (100)
CY-BOCS (Scalar variables, mean (SD))
Total baseline 24.6 (5.1) 24.4 (5.3) 24.3 (4.1) 23.0 (5.1) 26.2 (4.7) 24.9 (5.5) .061
Baseline obsessions 12.3 (2.8) 12.2 (2.8) 12.1 (2.2) 11.4 (3.0) 13.3 (2.4) 12.3 (3.1)
Baseline compulsions 12.3 (2.7) 12.2 (2.9) 12.2 (2.2) 11.6 (2.5) 12.9 (2.6) 12.5 (2.8)
Baseline comorbid disorders (K-SADS-PL)
Anxiety disorders 52 (19.3) 13 (16.7) 16 (33.3) 5 (19.2) 4 (9.8) 14 (20.0) .071
Depressive disorders 10 (3.7) 0 (0.0) 6 (12.5) 0 (0.0) 3 (7.3) 1 (1.4) .002
ADHD 24 (8.9) 2 (2.6) 9 (18.8) 0 (0.0) 9 (0.0) 13 (18.6) .001
ODD/CD 10 (3.7) 1 (1.3) 4 (8.3) 0 (0.0) 1 (2.4) 4 (5.7) .200
Tic 49 (18.6) 5 (6.4) 20 (41.7) 1 (3.8) 2 (4.90) 21 (30.0) .001
Number of co-occurring diagnoses
None 160 (59.5) 57 (75.0) 12 (25.5) 20 (76.9) 32 (78.0) 38 (54.3) .001
One 62 (23.0) 17 (22.4) 18 (38.3) 4 (15.4) 8 (19.5) 16 (22.9)
Two 23 (8.6) 1 (1.3) 11 (23.4) 1 (3.8) 1 (2.4) 9 (12.9)
Three or more 15 (5.6) 1 (1.3) 6 (12.8) 1 (3.8) 0 (0.0) 7 (10.0)
Note: SES ¼ Socioeconomic Status; CY-BOCS ¼ Children's Yale-Brown Obsessive Compulsive Scale; K-SADS-PL ¼ Schedule for Affective Disorders and Schizophrenia for
School-Age Children e Present and Lifetime version; ADHD ¼ Attention Deﬁcit Hyperactive Disorder; ODD/CD ¼ Oppositional Deﬁant Disorder/Conduct Disorder.
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based on the respective Clinical Global Impression-Severity (CGI)
scores, (3) a previous failed trial of exposure-based CBT for OCD
within less than 6 months prior to inclusion, (4) medication
treatment with an SRI less than 6 months prior to inclusion, and (5)
inadequate language proﬁciency by the patient or the parent.
Treatment
The exposure-based CBT treatment manual was based on the
study protocol designed by March and Mulle in collaboration with
Foa and Kozak (March, Mulle, Foa,& Kozak, 2000). The manual was
modiﬁed by adding more extensive family participation based on
the work of Piacentini, Langley, and Roblek (2007). The NordLOTS
exposure-based CBT regime consisted of 75minweekly sessions for
14 weeks. Parents were expected to accompany their children to all
sessions. The children were seen together with their parents in six
of the fourteen sessions (sessions 1e3, 5, 11, and 14). In the
remaining sessions, the child was treated individually for 45 min
and then the parents were seen with or without the child for an
additional 30 min. This extra timewas added speciﬁcally to address
issues regarding the parents' involvement in therapy, and their
attitude and feelings about their child's OCD symptoms.
In sessions one to three, the main focus was on psycho-
education, explaining the OCD and the treatment, including
detailed explanation of exposure and response prevention (E/RP).
Furthermore, the sessions included efforts to develop a symptom
hierarchy, formulate a treatment plan, and externalize the OCD. E/
RP exercises were initiated in session three and conducted in each
subsequent treatment session. The focus of the treatment was a
gradual exposure to threatening situations based on a detailed
symptom hierarchy, with the goal to reach the top of the hierarchy.
Homework exposure exercises were an essential part of thetreatment, parents were asked to support and monitor homework
assignments, at least for younger children. Towards the end of the
therapy, the emphasis shifted to generalizing skills and relapse
prevention.
Independent evaluation
IEs were experienced clinical psychologists and psychiatrists
from each of the three countries. All IEs were trained in the use of
the Schedule for Affective Disorders and Schizophrenia for School-
Age Children e Present and Lifetime version (K-SADS-PL) and the
CY-BOCS via formalized training procedures from a doctor-level
psychiatrist (the PI for the NordLOTS). The training was based on
observing and coding both taped and live K-SADS-PL and the CY-
BOCS interviews. Assessments were audiotaped; the same IEs
performed the assessment at baseline (K-SADS-PL and the CY-
BOCS), and at week 7 and post treatment (CY-BOCS). A random
sample of 30 audiotapes of baseline CY-BOCS interviews, out of a
possible 269 (11.2%), were evaluated by quality assurance (QA)
raters. The QA raters had extensive experience and expertise in the
use of the CY-BOCS. The analysis revealed that the intraclass cor-
relation coefﬁcient (ICC) was 0.94 (95% CI 0.85e0.97) for obses-
sions, 0.87 (95% CI 0.67e0.93) for compulsions and 0.92 (95% CI
0.78e0.97) for the total score. No reliability test was performed for
the K-SADS-PL.
All the therapy sessions were audiotaped and a random sample
of 280 (12.8%) treatment sessions out of a total of 2184 available
sessions were scored by the QA's for treatment ﬁdelity and thera-
pist competences all therapists were rated at least one time. The
randomly chosen sessions were evenly distributed across the 14
treatment sessions with at least one session from each patient. The
NordLOTS Treatment Integrity Scale (TIS) was used for determining
treatment ﬁdelity. The TIS was developed by the NordLOTS research
1 The analyses in this study were based on completers, the analyses were also
done with multiple imputations (MI), with almost identical results.
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form used in the POTS study (2004). Three categories of treatment
ﬁdelity were evaluated: (1) manual adherence, (2) competence in
manual delivery, and (3) therapist relational competencies. Scores
in each of these categories ranged from 1¼ very poor compliance to
4 ¼ very good compliance. All of the sessions were rated “good” or
“very good”, for overall manual adherence 94.7% (95% CI
91.4e96.8%), manual competence 96.0% (95% CI 93.0e97.7%), and
relational competencies 96.0% (95% CI 93.3e97.7%). For additional
information of this procedure, see Thomsen et al., 2013.
Measures
The following instruments were used as measures for inclusion,
and/or measures of treatment outcome:
Schedule for Affective Disorders and Schizophrenia for School-
Age Children e Present and Lifetime version (K-SADS-PL)
(Kaufman, Birmaher, Brent, & Rao, 1997). The K-SADS-PL is a semi-
structured diagnostic interview that assesses a range of child psy-
chopathology. The K-SADS-PL has good psychometric properties
with an interrater reliability of 98% and a 1e5 week test-retest
kappa of 0.80 for any anxiety disorder diagnosis (Kaufman et al.,
1997). Both convergent and divergent validity have been docu-
mented in a Nordic sample of adolescents (Lauth et al., 2010).
Symptoms can be classiﬁed as “not present”, “possible”, “in
remission”, or “certain”. In this study, OCD diagnoses and comor-
bidity were based on symptoms classiﬁed as certain only.
Children Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
(Scahill, Riddle, McSwiggin-Hardin, & Ort, 1997). The CY-BOCS is a
widely used, clinician-rated, semi-structured interview assessing
the severity of OCD symptomatology. The CY-BOCS evaluates the
severity of obsessions and compulsions, using10 items, across ﬁve
dimensions (time occupied by symptoms, interference, distress,
resistance and degree of control over symptoms). CY-BOCS shows
reasonable reliability and validity (Gallant et al., 2008; Scahill et al.,
1997; Storch et al., 2004). Good to excellent inter-rater agreement
with kappas of 0.91, 0.68 and 0.84 for obsessions, compulsions and
total score, respectively (Scahill et al., 1997). In the NordLOTS
sample, the inter-rater agreement with kappas of 0.94 (95% CI
0.85e0.97), for obsessions 0.87 (95% CI 0.67e0.93) for compulsions,
and 0.92 (95% CI 0.78e0.97) for total score.
Diagnostic, primary outcome and treatment response measures
Diagnostic status and comorbidity were assessed with the K-
SADS-PL (Kaufman et al., 1997), and OCD symptom severity was
assessed with the CY-BOCS (Scahill et al., 1997). The primary binary
indicator of treatment response was deﬁned as CY-BOCS total score
of 15, which corresponds to low to mild symptom severity levels.
Secondary outcome measures included: (1) clinical remission,
which was deﬁned as post treatment CY-BOCS total score of 10
indicating a more complete reduction of symptoms (Franklin et al.,
2011; Piacentini et al., 2011; POTS Treatment Study Team, 2004), (2)
30% reduction or more on the CY-BOCS total score (Storch, Lewin,
De Nadai, & Murphy, 2010; Tolin, Abramowitz, & Diefenbach,
2005), and (3) clinically signiﬁcant change and reliable change in-
dexes were also calculated according to the formulas reported in
Jacobson and Truax (1991). Clinical signiﬁcant change was deﬁned
as, criteria C in Jacobson and Truax (1991); the level of functioning
subsequent to therapy should fall outside the range of the general
dysfunctional population, when that range is deﬁned as extending
to two standard deviations of the mean of the population. Reliable
change was calculated using the formula CY-BOCS total pre-test
mean subtracted from the post-test mean, divided by the stan-
dard error of difference of the two scores (Jacobson & Truax, 1991).Data handling and statistical methods
The NordLOTS was registered in Current Controlled Trials
(www.controlled-trials.com ISRCTN66385119). The Centre for Child
and Adolescent Mental Health, Eastern and Southern Norway
(RBUP), was the main coordinating site. The database was built
using RBUP's data collection infrastructure program (Conﬁrmit
Horizons, version 17.0) on a secure research network. In addition to
collecting and monitoring data, the database provided ﬂow of pa-
tient information throughout the study. All analyses were con-
ducted using intent-to-treat (ITT) principles.
Statistical analyses on the scalar CY-BOCSwas conducted using a
linear mixed-effects model (Fitzmaurice, Laird, & Ware, 2011;
Gueorguieva & Krystal, 2004). Fixed effects were time (baseline,
week 7 and week 14), site, and the (time  site) interaction. In all
models, random effects included intercept and linear slope terms.
An unstructured covariance was used in order to account for within
patient correlation across time. Clinical response was analyzed
using Generalized Estimating Equations (GEE). When assuming
that data are missing at random, GEE models handle missing data
on the outcome as effectively as multiple imputations1 (Twisk & de
Vente, 2002; Ziegler & Vens, 2010). In the GEE models, time was
treated as a dichotomous variable (week 7 and 14). Study site and
(time  site) interactions were also included in the model.
Secondary outcome measures, clinical remission and 30%
reduction were analyzed by GEE in a similar fashion as the
dichotomous primary outcome. All analyses were conducted in the
R statistical program (R Development Core Team, 2008), with
packages nlme for mixed effects and gee for GEE analysis. The
syntax is available upon request from the corresponding author.
Results
Of all 269 patients, 241 (89.6%) completed the entire 14 weeks of
treatment (Fig. 1). Attrition by week 7 was 7.8% (n ¼ 21), total
attrition rate by week 14 was 10.4% (n ¼ 28).
Primary outcomes
The ITT linear-mixed effects model estimated mean and stan-
dard errors of CY-BOCS total scores by site are presented in Table 5.
The mixed effects model of the longitudinal total CY-BOCS score
revealed a signiﬁcant linear effect of time (F[1, 479] ¼ 130.434,
p < .001) and time site interaction (F[8, 479]¼ 2.557, p < .01). The
site effect at baseline was not signiﬁcant (F[4, 264]¼ 1.195, p > .05).
To assess treatment outcome differences by site, post-hoc pairwise
contrasts for the CY-BOCS total score at week 7 and post treatment
were conducted. There were signiﬁcant differences between site, at
week 7 (F[4, 264] ¼ 2.594, p ¼ .037). Additional, pairwise post-hoc
analysis between the ﬁve sites revealed that Aarhus site proved
superior to Southern and Eastern Norway (p ¼ .016), Central Nor-
way (p ¼ .009), and Gothenburg (p ¼ .021) sites, in getting early
responders. Notably, the post treatment outcomes, analysis did not
yield a signiﬁcant differences between sites in the overall model (F
[4, 264] ¼ 0.767, p ¼ .548) (Fig. 2).
Mean CY-BOCS total score symptom reduction from baseline to
post treatment was 52.9% (SD ¼ 30.9). Mean CY-BOCS obsession
subscale symptom reduction was 51.7% (SD ¼ 33.6) and mean
compulsion subscale symptom reduction was 53.6% (SD ¼ 32.1). A
paired t-tests (t[240] ¼ 1.5210, p ¼ .132) did not reveal signiﬁcant
differences between the CY-BOCS subscale post treatment.
Table 5
CY-BOCS scalar estimated total mean scores (SE).
Week Total n ¼ 269 Aarhus Denmark n ¼ 80 Gothenburg Sweden n ¼ 40 Stockholm Sweden n ¼ 30 Southern-eastern Norway n ¼ 41 Central Norway n ¼ 70
0 24.6 (0.40) 24.4 (0.72) 24.3 (0.93) 23.0 (1.18) 26.2 (1.01) 24.9 (0.77)
7 16.4 (0.45) 15.4 (0.81) 18.3 (1.00) 17.1 (1.25) 18.5 (1.03) 18.3 (0.78)
14 11.4 (0.41) 11.6 (0.75) 11.5 (1.01) 11.5 (1.27) 9.8 (1.10) 12.1 (0.80)
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for the fact that the two means were not independent) was 1.58
(95% CI: 1.37e1.80) (Morris & DeShon, 2002). Treatment response
(based on CY-BOCS total score of 15) was 72.6%, (95% CI
66.7e77.9%: n ¼ 175). Treatment response rate increased signiﬁ-
cantly from week 7 (38.3% [95% CI 32.4%e44.5%, n ¼ 95]).
Secondary outcomes
CY-BOCS total score was also dichotomized at 10 indicating
clinical remission. Post treatment 49.4% (95% CI 43.1%e55.6%:
n ¼ 119), were rated as clinical remitters. The rate of clinical
remission increased signiﬁcantly from week 7 (13.7%, [95% CI
10.0%e18.6%, n ¼ 34]). The percentage of participants who expe-
rienced a 30% reduction or more post treatment in the CY-BOCS
total score was 77.2%, (n ¼ 186). This was also a signiﬁcant in-
crease fromweek 7 (42.3%, [95% CI 36.4%e48.6% n¼ 105]). Based on
the criteria by Jacobson and Truax (1991), 69% (164) of the patients
evidenced clinically signiﬁcant change post treatment on the CY-
BOCS. This was corresponding with 70.1% (169) clinical reliable
change post-treatment, (CY-BOCS < 15). This was corresponding
with 70.1% (169) clinical reliable change on the CY-BOCS from pre-
to post-treatment (8 points or more on the CY-BOCS). By poolingFig. 2. Weekly adjusted intent-to-treat CY-BOCSthese indices, 53.5% (n ¼ 144) of the participants achieved both
clinically signiﬁcant change and clinical reliable change.
Discussion
The NordLOTS was conducted in three Scandinavian countries,
at ﬁve sites, in 20 regular community child and adolescents
outpatient clinics. This study is the largest treatment study of pe-
diatric OCD carried out to date, and also the ﬁrst multi-national,
multi-center treatment study in pediatric OCD. The large sample
size in this study is a signiﬁcant strength: compared to other
studies both open trials and RCTs, the current study sample
numbers three to four times as many patients (Table 1). Further-
more in NordLOTS, attrition rate was low; nine out of ten patients
completed the full treatment protocol. Clinicians successfully
guided the vast majority of patients through the time consuming
and, at times, uncomfortable aspects of exposure-based treatment.
Children and their parents showed a high degree of acceptance and
willingness to be treated with exposure-based CBT alone.
This study evaluated the effectiveness of 14 sessions of
manual-guided exposure-based CBT, with a family-based
approach. The aim was to investigate the effectiveness and
transportability of such treatment, in busy ordinary communitytotal score by treatment site, with 95% CI.
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mentation of EBP in community settings is widely debated and
demands a close collaboration between clinicians and researchers.
One of the major challenges reported by both is the lack of
demonstrated success in transporting treatments from the
university-based to community settings (Weisz, Weiss, &
Donenberg, 1993). The current study offers an important contri-
bution to treatment research in pediatric OCD, by presenting a
successful example of transportability of a university developed
treatment into community mental health clinics.
In the NordLOTS study, pediatric patients treated with
exposure-based CBT, showed a high treatment response, seven out
of ten patients were rated as responders by independent evalua-
tors. The results are comparable to several previous open trials
conducted at expert sites (Franklin et al., 1998; March, Mulle, &
Herbel, 1994; Storch, Lehmkuhl, et al., 2010; Storch, Lewin, et al.,
2010). Moreover, due to the broad inclusion criteria and the var-
ied mental health settings in which the trial was conducted,
generalizability of the ﬁndings in the NordLOTS study to the clinical
settings in which most pediatric OCD patients receive care is likely
to be high. Our data add evidence for the clinical utility of exposure-
based CBT as a ﬁrst-line treatment for pediatric OCD.
There were no signiﬁcant site differences at post treatment,
despite substantial differences between the various settings (i.e.,
OCD clinics versus communityebased clinics, demographic varia-
tions including nationality, urban versus rural catchment areas for
sites, clinic size, and comorbidity). The fact that there were no
signiﬁcant differences between the regular outpatient clinics and
OCD clinics is especially notable and consistent with previous
ﬁndings from smaller trials. Exposure-based CBT treatment is
effective for pediatric OCD in a wide variety of settings (Bolton &
Perrin, 2008; Valderhaug, Larsson, Gotestam, & Piacentini, 2007).
The results support the generalizability of the CBT outcome from
smaller scale efﬁcacy studies of CBT to community outpatient child
and adolescent mental health clinics.
The severity of OCD symptoms decreased signiﬁcantly over the
course of treatmentwith an observed uncontrolled (adjusted) effect
size of 1.58 (95% CI: 1.37e1.80), indicating that CBT treatment is
associated with large treatment effect, and absolutely comparable
with RCTs (Table 1). The mean CY-BOCS score post treatment was
11.4, which is close to the cut off for clinical remission. Mean
symptom reduction in NordLOTS was 52.9%, which is consistent
with other studies (Benazon, Ager,& Rosenberg, 2002; March et al.,
1994;Wever&Rey,1997). Nearly half of the patientsweredeﬁned as
being in remission, exceeding the rates reported in most previous
studies (Piacentini et al., 2011; POTS Treatment Study Team, 2004).
Another strength of this study was the examination of clinical
signiﬁcant and reliable change. Based on criteria by Jacobson and
Truax (1991) 69% (n ¼ 164/241) of the patients achieved clinically
signiﬁcant change from baseline to post treatment CY-BOCS, with
70.1% (n ¼ 169/241) of the patients meeting criteria for reliable
change. These ﬁndings indicate that the statistically signiﬁcant
reduction found in this sample, which were comparable to those
achieved in expert sites around the world, were also clinically
meaningful.
The CY-BOCS, as an outcome measure, has often been reported
using either a dichotomization or percentage reduction (Geller,
Biederman, Stewart, Mullin, Martin, et al., 2003; Storch,
Lehmkuhl, et al., 2010; Storch, Lewin, et al., 2010). In this study,
we used clinical response deﬁned as a CY-BOCS score of ﬁfteen or
less as our primary outcome measure, and a reduction of thirty
percent or more on the CY-BOCS as a secondary outcome. Our
deﬁnition of clinical response at 15 on the CY-BOCS total score,
might inﬂate the rate of responders. It is possible, for example,
that some patients with a CY-BOCS score just above the cut-offwhen entering treatment, and a score just below the cut-off for
clinical response at week 13 improved due to chance or normal
ﬂuctuation of symptoms, rather than as an effect of treatment.
There were, however, only 6 patients (2.2%) who were deemed
responders (CY-BOCS  15) and who did not obtain 30% or more
reduction on the CYBOCS from baseline to post treatment. There
was in fact very little difference between the results on treatment
response (72.6%), 30% reduction (77.2%) and clinical reliable
change (70.1%). Future studies should examine the validity of
various response and remission criteria (e.g. convergence with
functional improvement) to guide the ﬁeld regarding the optimal
deﬁnitions of both.
NordLOTS was not sponsored by industry funding and pa-
tients from a variety of regular community child and adolescent
outpatient clinics participated. Independent raters were used to
assess all outcome measures and therapy adherence and ﬁdelity
were excellent. None of the patients in The NordLOTS's primary
treatment step received medication for their OCD, which is quite
unusual in such a large treatment study. This enables examina-
tion of the effects of CBT treatment without introduction of
medication confounds. This is also important with regard to
patient inclusion. NordLOTS was likely to enroll patients who,
because their parents might be against medication use for their
children, are unlikely to be enrolled in clinical trials where
randomization to medication is a possibility (Benazon et al.,
2002).
Limitations
The ﬁrst step of the NordLOTS was an uncontrolled trial, and the
usual threats to internal validity apply here, including the potential
effects of time, history, andmaturation (Chambless&Hollon, 2012).
The degree to which these factors inﬂuenced the outcomes cannot
be directly determined. However, given the strong and consistent
treatment effects observed here, in concert with over a dozen
randomized trials worldwide attesting to efﬁcacy of exposure-
based CBT for OCD (Barrett, Healy-Farrell, & March, 2004; Bolton
et al., 2011; de Haan, Hoogduin, Buitelaar, & Keijsers, 1998; Pia-
centini et al., 2011; POTS Treatment Study Team, 2004), and a
generally low placebo response rate for OCD across many studies
and contexts, it seems unlikely that these factors could explain the
overall improvement.
The lack of ethnic diversity in the sample, is a limitation. As
reported 97% of the patients were of Scandinavian ethnicity and
therefore the generalizability to more ethnically diverse countries
and clinics is uncertain. However, this problem (i.e., limited ethnic
diversity) is highly consistent with the existent OCD literature
(Williams, Powers, Yun, & Foa, 2010). Another limitation is that the
implementation of the manualized exposure-based CBT with a
family-based treatment, the training and supervision of the ther-
apists conducted hereinmay be difﬁcult to obtain under ordinary or
non-research conditions. We argue that similar or at least sufﬁcient
conditions comparable to what was done her may also be possible
in full-scale implementation. Furthermore, as this treatment has
shown to be effective in a large proportion of patients, arguments
for cost effectiveness for the whole procedure could easily be
derived from this study.
Conclusion
NordLOTS is the largest treatment study for pediatric obsessive-
compulsive disorder using cognitive behavior therapy as the initial
treatment. This study has demonstrated that manual-guided CBT
can be applied effectively in community child and adolescents
mental health clinics.
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